Investment Rating - The industry investment rating is "Outperform the Market" (maintained) [2] Core Insights - The 2026 Central Document emphasizes agricultural modernization, focusing on stabilizing grain production, promoting healthy development in animal husbandry, and enhancing agricultural technology innovation [3][4][5] - The grain production target has been raised to approximately 1.4 trillion jin, with initiatives to improve grain quality and variety [5][6] - The document acknowledges the success of previous measures in the livestock sector and introduces new strategies to boost dairy product consumption [8][9] - Agricultural technology innovation is highlighted, with a focus on the implementation of breeding actions and the integration of AI in agriculture [15][21] Summary by Sections Grain Sector - The document sets a grain production target of stabilizing at around 1.4 trillion jin and emphasizes quality improvement and variety enhancement [5][7] - It includes measures to protect farmers' interests, such as determining minimum purchase prices for rice and wheat [5][7] - The document also stresses the importance of developing a futures market for agricultural products [5][7] Livestock Sector - The document reinforces the need for comprehensive regulation of pig production capacity and acknowledges the success of previous measures in stabilizing the beef and dairy industries [8][9][11] - It promotes measures to enhance dairy product consumption and supports the development of forage crops [9][11] Agricultural Technology - The document continues to emphasize the implementation of breeding actions and the promotion of breakthrough varieties [15][16][17] - It encourages the development of high-end intelligent agricultural machinery and the integration of AI, drones, and IoT into agricultural practices [21][25] Investment Recommendations - The report recommends several companies across different segments, including: - Livestock: YouRan Agriculture, Modern Agriculture [27] - Swine: HuaTong Co., DeKang Agriculture, MuYuan Co., Wen's Co., TianKang Bio, and ShenNong Group [27] - Pet Industry: GuaiBao Pet [27] - Feed: HaiDa Group [27] - Poultry: LiHua Co., YiSheng Co., and ShengNong Development [27] - Animal Health: HuiSheng Bio [27] - Planting Chain: Hainan Rubber, QuanYin High-Tech, Guotou Fengle, and LongPing High-Tech [27]

Core Insights - The report emphasizes a favorable outlook for the livestock sector, particularly dairy farming, anticipating a significant cyclical reversal benefiting Hong Kong-listed dairy farming companies [1][12] - The investment strategy highlights a recommended monthly portfolio including leading companies in various segments such as dairy, pig farming, and pet food [1][3] Livestock Sector - The livestock sector is expected to experience a cyclical reversal, with both beef and milk prices projected to rise, driven by a reduction in domestic beef production and a historical low in milk prices [14][29] - Key recommendations include Yuran Dairy and Modern Farming, which are positioned to benefit from the anticipated price recovery in raw milk and beef [14][17] Pig Farming Sector - The pig farming sector is witnessing a stabilization in prices, with a notable increase in piglet prices, indicating a potential recovery in profitability for leading companies [20][21] - Recommended companies in this sector include Muyuan Foods, Wens Foodstuffs, and Huazhong Holdings, which are expected to benefit from improved cash flow and dividend returns [3][15] Poultry Sector - The poultry sector is seeing a slight increase in supply, with expectations of demand recovery supporting price stability, particularly for broiler chickens [22][24] - Leading companies such as Lihua Agricultural and Shengnong Development are highlighted for their competitive advantages in cost management and market positioning [18][19] Pet Food Sector - The pet food market is identified as a high-growth area, benefiting from rising consumer sentiment and the emergence of domestic brands [16][18] - Companies like Guibao Pet Food are recommended for their strong growth potential in this segment [3][16] Feed Sector - The feed industry is expected to deepen its industrialization, with leading companies leveraging technological and service advantages to enhance competitive positioning [1][3] - The report notes that feed prices are at historical lows, providing a supportive cost structure for producers [20][21] Agricultural Products - The report tracks agricultural product prices, noting fluctuations in pork, chicken, and feed prices, with implications for overall market dynamics [2][21] - The analysis indicates that soybean meal prices are at historical lows, while corn prices are stabilizing, suggesting a tightening supply-demand balance in the medium term [20][21]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The pig price is weakening, and supply pressure remains after the festival, with the current industry breeding profit turning positive and the sentiment for replenishment continuing to recover [2][12] - The industry policy is undergoing a profound transformation, focusing on protecting farmers' rights and activating enterprise innovation, which may lead to a better performance of growth stocks in the future [3][12] - The high-quality development of the industry is imperative, with cost-leading and farmer-linked enterprises likely to enjoy excess profits and valuation premiums [3][13] Summary by Sections 1. Swine Industry - The swine breeding sector has seen a slight increase of 0.2%, gradually digesting concerns about slow capacity reduction [2][12] - The average weight of pigs for slaughter has decreased from high levels, with prices adjusting weakly to 12.31 CNY/kg [2][12] - The price of 7 kg piglets has risen to 367 CNY, indicating a weak expectation for capacity reduction [2][12] - The policy shift towards protecting farmers' rights and promoting innovation is expected to positively influence pig prices and profitability in 2026 [3][12] 2. Poultry Industry - The poultry sector is experiencing a contradiction of "high capacity, weak consumption," with the price of broiler chickens at 3.7 CNY/kg, down 3.4% week-on-week [4][13] - The impact of avian influenza in France may lead to a reduction in imported breeding chickens, potentially increasing prices for parent stock [4][13] - Integrated enterprises and contract farming are expected to expand market share in 2026 [4][14] 3. Feed Industry - The prices of various aquatic products have rebounded, with significant year-on-year increases for some species [5][15] - Hai Da Group is recommended due to its clear long-term growth path and plans to increase its dividend payout ratio [6][15][16] - The company aims for a global sales target of 100 million tons by 2050, with ongoing overseas market expansion [6][16] 4. Pet Industry - The pet industry is facing pressure with concerns over Q4 2025 performance, but there are signs of recovery in domestic sales [7][17] - Companies like Zhongchong and Peidi are recommended for their strong domestic sales growth potential [7][17] 5. Agricultural Products - Domestic soybean meal prices have increased slightly, supported by weather disturbances and procurement demand [8][18] - Corn prices have shown fluctuations, with a slight decrease due to reduced channel stocking [8][18] - The price of eggs has decreased, indicating a potential peak in trade inventory [8][18]

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-011 天康生物股份有限公司 独立董事候选人声明与承诺 声明人李刚作为天康生物股份有限公司第九届董事会独立董事候选人，已充 分了解并同意由提名人天康生物股份有限公司董事会提名为天康生物股份有限 公司（以下简称该公司）第九届董事会独立董事候选人。现公开声明和保证，本 人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及 独立性的要求，具体声明并承诺如下事项： 一、本人已经通过天康生物股份有限公司八届董事会提名委员会资格审查， 提名人与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定 ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-008 天康生物股份有限公司 独立董事提名人声明与承诺 提名人天康生物股份有限公司董事会现就提名李刚为天康生物股份有限公 司第九届董事会独立董事候选人发表公开声明。被提名人已书面同意作为天康生 物股份有限公司第九届董事会独立董事候选人（参见该独立董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人 任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过天康生物股份有限公司第八届董事会提名委员会资格 审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切 关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________ ...

一、本人已经通过天康生物股份有限公司八届董事会提名委员会资格审查， 提名人与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-012 天康生物股份有限公司 独立董事候选人声明与承诺 声明人陈克峰作为天康生物股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人天康生物股份有限公司董事会提名为天康生物股份 有限公司（以下简称该公司）第九届董事会独立董事候选人。现公开声明和保证， 本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法 规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资 格及独立性的要求，具体声明并承诺如下事项： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规 ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-010 天康生物股份有限公司 独立董事候选人声明与承诺 声明人屈勇刚作为天康生物股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人天康生物股份有限公司董事会提名为天康生物股份 有限公司（以下简称该公司）第九届董事会独立董事候选人。现公开声明和保 证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选 人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过天康生物股份有限公司八届董事会提名委员会资格审查， 提名人与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担 任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规 ...

提名人天康生物股份有限公司董事会现就提名陈克峰为天康生物股份有限 公司第九届董事会独立董事候选人发表公开声明。被提名人已书面同意作为天康 生物股份有限公司第九届董事会独立董事候选人（参见该独立董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人 任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过天康生物股份有限公司第八届董事会提名委员会资格 审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切 关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 天康生物 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 证券代码：002100 证券简称：天康生物 公告编号：2026-009 天康生物股份有限公司 独立董事提名人声明与承诺 如否，请详细说明：_____________________________ ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-007 天康生物股份有限公司 独立董事提名人声明与承诺 提名人天康生物股份有限公司董事会现就提名屈勇刚为天康生物股份有限 公司第九届董事会独立董事候选人发表公开声明。被提名人已书面同意作为天康 生物股份有限公司第九届董事会独立董事候选人（参见该独立董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人 任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过天康生物股份有限公司第八届董事会提名委员会资格 审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切 关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_____________________ ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2026-013 天康生物股份有限公司 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 鉴于天康生物股份有限公司（以下简称"公司"）第八届董事会任期即将届 满，根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》《公司章程》等有关规定，公司于 2026 年 2 月 2 日召开第八届董事会第三 十二次（临时）会议，审议通过《关于公司董事会换届选举第九届董事会非独立 董事的议案》《关于公司董事会换届选举公司第九届董事会独立董事的议案》。 上述议案尚需提交公司股东会审议。具体情况如下： 一、董事会换届选举情况 （一）第九届董事会组成 根据《公司法》和《公司章程》的相关规定，公司董事会由 7 名董事组成， 其中非独立董事 4 名，独立董事 3 名，其中 1 名独立董事为会计专业人士。任期 自公司股东会审议通过之日起三年。 （二）第九届董事会董事候选人的情况 1、非独立董事候选人 公司 ...